Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, Novartis uses innovative science and digital technologies to create transformative treatments in areas of great medical need. In its quest to find new medicines, Novartis consistently ranks among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and the company is finding innovative ways to expand access to its latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

The company applies its expertise, people and full organizational capability to address major, unresolved global health challenges with the aim of transforming health in lower-income populations. It aligns its global health work with the Novartis access principles, leveraging research and development to address unmet needs, expanding affordable access through novel pricing and business models, and working with partners to strengthen health systems. Novartis aims to adopt an integrated end-to-end approach to disease management for the elimination or control of four diseases where there has been market failure and little investment in R&D: sickle cell disease, Chagas disease, malaria and leprosy. In sub-Saharan Africa, the company is implementing a targeted strategy focused on reaching more patients and expanding the availability of our full portfolio of medicines.

Find out more at: https://www.novartis.com